Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-043287
Filing Date
2025-05-14
Accepted
2025-05-14 16:06:03
Documents
92
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0241615-10q_immucell.htm   iXBRL 10-Q 954383
2 CERTIFICATION ea024161501ex31-1_immucell.htm EX-31.1 9414
3 CERTIFICATION ea024161501ex31-2_immucell.htm EX-31.2 9381
4 CERTIFICATION ea024161501ex32-1_immucell.htm EX-32.1 4565
5 CERTIFICATION ea024161501ex32-2_immucell.htm EX-32.2 4603
  Complete submission text file 0001213900-25-043287.txt   6630534

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE iccc-20250331.xsd EX-101.SCH 56187
7 XBRL CALCULATION FILE iccc-20250331_cal.xml EX-101.CAL 39591
8 XBRL DEFINITION FILE iccc-20250331_def.xml EX-101.DEF 291617
9 XBRL LABEL FILE iccc-20250331_lab.xml EX-101.LAB 537992
10 XBRL PRESENTATION FILE iccc-20250331_pre.xml EX-101.PRE 317319
95 EXTRACTED XBRL INSTANCE DOCUMENT ea0241615-10q_immucell_htm.xml XML 779573
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12934 | Film No.: 25945364
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)